Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5937
    +0.0002 (+0.04%)
     

  • NZD/EUR

    0.5543
    +0.0002 (+0.04%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.84
    +0.03 (+0.04%)
     

  • GOLD

    2,328.90
    -13.20 (-0.56%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • NZD/JPY

    92.1110
    +0.3450 (+0.38%)
     

Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits

Margaret Patrick
Updated
Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits

Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18. In 4Q17, the company also submitted a supplemental application to the Japanese Ministry of Health, Labour and Welfare for updating Tresiba’s label to reflect hypoglycemia data from the DEVOTE trial. Novo Nordisk is anticipating a readout of the results from its trial comparing Tresiba to insulin glargine U300 in 4Q18.

Continue reading